Mise à jour corporative de Kintavar
29 mai 2024 07h43 HE
|
Kintavar Exploration inc.
MONTRÉAL, 29 mai 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (la « Société » ou « Kintavar ») (TSX-V : KTR), est heureuse de fournir une mise à jour corporative détaillant les objectifs...
Kintavar Corporate Update
29 mai 2024 07h43 HE
|
Kintavar Explorations Inc.
MONTREAL, May 29, 2024 (GLOBE NEWSWIRE) -- Kintavar Exploration Inc. (the “Corporation” or “Kintavar”) (TSX-V: KTR), is pleased to provide a corporate update detailing the Corporations objectives...
Odysight.ai Announces First Quarter 2024 Financial Results and Provides Corporate Update
16 mai 2024 08h30 HE
|
Odysight.ai Inc.
OMER, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive maintenance (PdM) and condition-based monitoring (CBM) solutions,...
Optimi Health Provides Corporate Update
10 mai 2024 08h50 HE
|
Optimi Health Corp.
Optimi Health provides corporate update.
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
02 mai 2024 07h30 HE
|
Arbutus Biopharma Corporation
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
25 avr. 2024 08h35 HE
|
NurExone Biologic Inc
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility
Solar Alliance first quarter corporate update shows continued growth for commercial solar
15 avr. 2024 07h59 HE
|
Solar Alliance Energy Inc.
TORONTO and KNOXVILLE, Tenn., April 15, 2024 (GLOBE NEWSWIRE) -- Solar Alliance Energy Inc. (‘Solar Alliance’ or the ‘Company’) (TSX-V: SOLR), a leading solar energy solutions provider focused on...
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
01 avr. 2024 07h35 HE
|
GRI Bio, Inc.
Ongoing Phase 2a biomarker study evaluating lead program GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) with interim data expected H1 2024 and topline data expected H2 2024 ...
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise
27 mars 2024 17h05 HE
|
NurExone Biologic Inc
Gross Proceeds close of $4M CAD Generated for NurExone from Warrants Exercise
Odysight.ai Announces 2023 Financial Results and Provides Corporate Update
27 mars 2024 08h30 HE
|
Odysight.ai Inc.
Revenues increased in more than 350% from its commercial contracts OMER, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (OTCQB: ODYS), a leading provider of visual based predictive...